



WHAT IS CLAIMED IS:

1. (amended) A method for impairing movement of a cutaneous lymphocyte-associated antigen⁺ (CLA⁺) memory T-cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antibody against cutaneous-T-cell-attracting chemokine (CTACK), whereby administration of said antibody impairs movement of said cutaneous lymphocyte-associated antigen⁺ memory T-cell within or to the skin of said mammal.
3. (amended) The method of Claim 1, wherein said movement is within said skin.
4. (amended) The method of Claim 1, wherein said antibody neutralizes cutaneous-T-cell-attracting chemokine.
22. (amended) A method ~~of~~ for treating a patient suffering from a skin disorder comprising administering an effective amount of an ~~antagonist~~ antibody against ~~CTACK~~ cutaneous-T-cell-attracting chemokine.
- ~~23. The method of Claim 22, wherein the antagonist is an antibody.~~
24. (new) The method of Claim 1, wherein said administering is local, systemic, topical, subcutaneous, intradermal, or transdermal.
25. (new) The method of Claim 1, wherein said cutaneous lymphocyte-associated antigen⁺ memory T-cell moves into the dermis or epidermis of said skin.
26. (new) The method of Claim 22, wherein said skin disorder is inflammation.
27. (new) The method of Claim 22, wherein said skin disorder is allergic-contact dermatitis.
28. (new) The method of Claim 22, wherein said skin disorder is psoriasis.
29. (new) The method of Claim 22, wherein said skin disorder is wound healing,
30. (new) The method of Claim 22, wherein said skin disorder is cancer.
31. (new) The method of Claim 22, wherein said skin disorder is carcinoma.
32. (new) The method of Claim 22, wherein said skin disorder is infection.
33. (new) The method of Claim 32, wherein said infection is microbial, viral, or parasitic.